Evaluation of Patient-Reported Outcomes with Etanercept in Moderate to Severe Plaque Psoriasis Patients After Therapy With Apremilast

April 2020 | Volume 19 | Issue 4 | Original Article | 378 | Copyright © April 2020


Published online March 6, 2020

Jerry Bagel , Bradley S. Stolshek , Yue Yang , Gregory Kricorian , Leon Kircik

aPsoriasis Treatment Center of Central New Jersey, East Windsor, NJ bAmgen Inc., Thousand Oaks, CA cIcahn School of Medicine, Mount Sinai, New York, NY; Indiana Medical Center, Indianapolis, IN; Physicians Skin Care, PLLC; DermResearch, PLLC, Louisville, KY

42.9% (45.3), 56.4% (40.1), 67.7% (29.3), and 80.1% (24.7) in the overall study population and patients who achieved PASI 50, 75, and 90, respectively (Figure 1). Among the overall study population, the percent of greatest change observed from baseline in PASI and PSI followed similar patterns (Figure 2); however, the PSI appeared to improve more rapidly than PASI clinical outcome score during etanercept treatment. For individual PSI item scores, mean (SD) percent improvement across each of the 8 items was similar to PSI total score at the different levels of PASI achievement. Among patients who achieved PASI 50, PASI 75, and PASI 90, itch improved by 57.9% (39.9), 72.0% (28.2), and 89.8 (15.5) at week 12 and 50.2% (46.0), 59.8% (38.3), and 74.0% (26.3) at week 24, respectively. Redness improved by 55.5% (32.6), 61.3% (31.6), and 82.4% (18.4) at week





<img